logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Denosumab: best bone-modifying agent in setting of HR+ breast cancer and AIs?

Network meta-analysis finds denosumab increases BMD and decreases fracture risk.